Ularitide for the treatment of acute decompensated heart failure: from preclinical to clinical studies.
Bottom Line: There is an unmet need for new therapy options with new drugs with a new mode of action.One of the drugs currently in clinical testing in Phase III is ularitide, which is the chemically synthesized form of the human natriuretic peptide urodilatin.In animal models of heart failure as well as Phase I and II clinical studies in heart failure patients, ularitide demonstrated beneficial effects such as symptom relief and vasodilation, while still preserving renal function.
Affiliation: Department of Innovative Clinical Trials, University Medical Centre Göttingen, Göttingen, Germany firstname.lastname@example.org.Show MeSH
Related in: MedlinePlus
Mentions: In the ularitide groups, more patients assessed their dyspnoea as moderately or markedly improved (Figure 5A), whereas in the placebo group, patients most frequently reported no change. The gradual decrease of PCWP at 6 h correlated well with pooled ularitide- and placebo-treated patients' dyspnoea assessments (Figure 5B).Figure 5
Affiliation: Department of Innovative Clinical Trials, University Medical Centre Göttingen, Göttingen, Germany email@example.com.